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Abstract
Purpose: The purpose of this study was to determine if oral health education
increases oral health related quality of life in gynecologic oncology patients.
Methods: In this pilot study, 23 participants (18 - 70+ years) with a history of
gynecologic cancer were recruited to participate in the study. Participants
completed an Oral Health Impact Profile (OHIP-14) questionnaire prior to and
after given education packet.
Results: At baseline, the mean pre-test OHIP-14 score was 6.7 (SD 8.4) and mean
OHIP-14 post-test score was 8.8 (SD 8.4). Pearson Correlation was .90. P (T< = t)
one-tail p < .008. Demonstrating statistical significance.
Conclusion: OHIP-14 scores increased after four-weeks, higher scores of OHIP14 will always be equal to a negative impact of quality of life, demonstrating that
there was an overall decrease in OHRQoL amongst this population of
gynecologic cancer patients after implementation of oral health education.
However, when data was analyzed individually participants who had been treated
with surgery + radiation as well as participants who had been diagnosed with
uterine cancer OHRQoL improved after implementation of education, but no
significance was found.
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Introduction/Literature Review
Introduction to the Research Question
Prevention and education of oral care prior to cancer treatments is important for
quality of life (QoL) and oral health. During cancer treatment patients may have an
increase in dental caries, hyposalivation, taste alterations, mucosal sensitivity, and loss of
appetite (Aktas & Terzioglu, 2015). Research has demonstrated changes to the oral cavity
during oropharyngeal, breast, and head and neck chemotherapy and radiation. However,
changes to the oral cavity during gynecologic oncology treatments have not been
evaluated.
According to the Centers for Disease Control (2019), between 2012 and 2016
94,000 women were diagnosed yearly with a gynecologic cancer. Gynecologic cancer is
categorized into eight categories: cervical, ovarian, uterine, vaginal, vulvar, fallopian
tube, peritoneal, and gestational trophoblastic disease. Gynecologic cancer treatments can
directly affect a woman’s self- esteem as well as physical and social well-being, and
complicating daily life activities, thus potentially reducing QoL (Aktas & Terzioglu,
2015). However, there is a paucity of research on how gynecologic cancer treatments can
affect oral health related quality of life (OHRQoL). Health-related quality of life
(HRQoL) assessment of women with ovarian cancer has been implemented into patient
care in most trials by NRG Oncology and is being adapted to standard of care
(Grzankowski & Carney, 2011). The benefits of using OHRQoL assessment include
better patient-provider communication and overall improvement of QoL (Grzankowski &
Carney, 2011). However, research lacks in the impact gynecologic oncology therapies
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have on oral changes during oncology treatments and how those changes effect
OHRQoL. Assessing cancer patient’s OHRQoL has important implications for the
clinical practice of dentistry and dental research. A multidimensional construct, OHRQoL
includes a subjective evaluation of the individual’s oral health, function, emotional wellbeing, expectations and satisfaction with care, and sense of self (Sicho & Broder, 2011).
Within the dental community there is an interest in increasing dental care knowledge and
understanding oral changes that may occur during gynecologic oncology treatments. Oral
and dental care have been recommended before, during, and beyond oncology treatment
as well as oral hygiene education prior to treatment therapy. The purpose of this study is
to determine if oral health education increases OHRQoL in gynecologic oncology
patients.
Statement of Problem
Research suggests the positive impact of oral health education for oncology
patients before, during, and beyond oncology treatment. However, there is a paucity of
evidence in evaluating gynecologic oncology treatments on oral health and in turn effects
on QoL. Implementing and providing oral health education has the potential to improve
the OHRQoL during and beyond treatment.
Research Questions
This study identified whether educating gynecologic oncology patients on oral
hygiene had an impact on oral health and QoL. This study aimed to answer the following
research questions.
1. What is the impact of gynecologic cancer treatments on OHRQoL?
2. Is there an improvement in OHRQoL secondary to oral hygiene education?
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Overview of Research
Assessing oral health education and OHRQoL of gynecologic oncology patients is
a relatively ignored area of research. There is literature on other cancer treatments
suggesting positive impact of oral health education and outcomes. Therefore, one can
extrapolate that the same educational efforts in gynecologic oncology patients would
have the same observed benefits. Implementing and providing oral health education prior
to treatment has the potential to improve the OHRQoL during and after treatment, thus
affecting patients’ QoL.
Research conducted by Toth et al., (1995) provides evidence that cancer therapies
place patients at a greater risk for oral health complications during treatment.
Unfortunately, prevention, education, and treatment of such complications are often
overlooked. Toth et al., suggests more emphasis is needed in oral health management,
education, prevention, and dental treatment. The National Institute of Dental and
Craniofacial Research (NIDCR) guidelines for the provision of oral care for patients with
cancer recommended patients have a dental visit prior to beginning cancer treatment. The
NIDCR also provides suggestions for care during chemotherapy and radiation; however
currently there is no universally accepted dental protocol. It is well documented that poor
oral health is associated with an increased incidence and severity of oral complications
therefore, the dental team’s involvement may reduce the risk of such complications
(Taichman & Tindle, 2016). Cancer treatments can also directly affect a women’s selfesteem, physical and social well-being, thereby complicating daily life activities, and thus
potentially reducing their QoL. Patients receiving cancer treatments may be at a higher
risk for developing caries (cavities), hyposalivation, taste alterations, mucosal sensitivity,
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and loss of appetite (Aktas & Terzioglu, 2015); These complications may directly impact
QoL. As the number of cancer survivors increases, it is becoming abundantly clear that
aggressive management of oral toxicities is needed to ensure both short-term and longterm oral health, as well as general well‐being (Epstein et al., 2012).
OHRQoL.
According to the United States Surgeon General’s report on oral health, OHRQoL
is “a multidimensional construct that reflects (among other things) people’s comfort
when eating, sleeping, and engaging in social interaction; their self-esteem; and their
satisfaction with respect to their oral health.” (US Department of Health and Human
Services, 2000, p.135). The World Health Organization (WHO) recognizes oral health
and QoL as an integral part of general health and well-being and is an important section
of the Global Oral Health Program (WHO, 2020).
Figure 1
Determinates of OHRQoL

Note. From “Oral Health Related Quality of Life,” by de la Fuente Hernandez et al.,
2014. Copyright 2015 by The Author(s). License IntechOpen.
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The Oral Health Impact Profile (OHIP) is the most widely used QoL survey to
evaluate the influence of oral diseases on individuals (Barrios et al., 2015). The short
form OHIP-14 by Slade (1996), contains 14 items grouped into seven dimensions of
impact: functional limitation, physical pain, psychological discomfort, physical disability,
psychological disability, social disability, and handicap. Research by Al Shamrany, 2006
found the OHRQoL survey has a broader appreciation of the impact of oral health and
should provide the basis for any oral health program development. Oral health care
providers are urged to integrate the OHRQoL concept into their daily practice to improve
the outcome of their services.
Types of and Standard Therapy Protocols for Gynecologic Cancer.
Gynecologic cancer affects a woman’s reproductive organs. According to Yale
Medicine (2020), gynecologic cancers are rare and occur in about 100,000 women in the
United States each year. That being said, all women are at risk for developing
gynecologic cancers and this risk increases with age. It is imperative to know the warning
signs, as treatments are most successful with early detection (Yale Medicine, 2020).
There are eight categories of gynecologic cancers: cervical, uterine, ovarian, fallopian,
peritoneal, vaginal, vulvar, and gestational trophoblastic disease. Each type of
gynecologic cancer is unique with different signs and symptoms, risk factors, and
prevention strategies (Robert H. Lurie Comprehensive Cancer Center of Northwestern
University, 2020). Treatment for the gynecologic cancers can include surgery,
chemotherapy, radiation, clinical trial, and a combination of the aforementioned.
Furthermore, treatment is determined by the type of malignancy, staging and grade,
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metastasis of the cancer, overall health of the patient, and treatment preference (American
Cancer Society [ACS], 2020b).
Cervical Cancer
Cervical Cancer is a disease where cancer cells form in the cervix. The cervix is
the lower end of the uterus that leads from the uterus to the vagina. Major risk factors for
women developing cervical cancer include being infected with Human Papilloma Virus
(HPV) and exposure to diethylstilbestrol (DES) in utero (National Cancer Institute [NCI],
2020a). There are usually no signs and symptoms with early cervical cancer; however, it
can be detected with early and regular check-ups. Signs and symptoms of cervical cancer
included vaginal bleeding, unusual vaginal discharge, pelvic pain, and pain during sexual
intercourse. Tests to detect and diagnose cervical cancer consist of physical exams and
review of health history, pelvic examination, Papanicolaou smear test (Pap smear test),
HPV test, endocervical curettage, colposcopy, and biopsy. Prognosis depends on the
stage of the cancer, type of cancer cells, patient’s age and health, presence of HPV, HIV
positive or negative status, and whether the cancer is newly diagnosed or recurrent (NCI,
2020a). Treatment for cervical cancer depends on the stage, type, patient’s desire to have
children, and their age. Staging for cervical cancer includes Stage I, Stage II, Stage III,
and Stage IV (NCI, 2020a). See Figure 2 for staging and treatment options.
Uterine Cancer
Uterine or endometrial cancer is a disease where cancer cells form in the
endometrium tissues. The endometrium is the lining of the uterus where a fetus may grow
(NCI, 2020b). Major risk factors for uterine cancer are obesity and metabolic syndrome
where the female has high blood pressure, high blood sugar, excess body fat around their

PILOT STUDY of OHRQoL DURING GYN CANCER TREATMENT

7

waist, and abnormal cholesterol levels. Other risk factors include taking estrogen only
hormone replacement therapy (HRT) after menopause, taking tamoxifen to prevent or
treat breast cancer, type 2 diabetes, nulliparous (never giving birth), start of menstruation
at an early age, menopause at a later age, polycystic ovarian syndrome (PCOS), family
history of uterine cancer, genetic conditions such as hereditary nonpolyposis colorectal
cancer (HPNCC) or Lynch Syndrome, endometrial hyperplasia, and age (NCI, 2020b).
Some signs and symptoms of uterine cancer are vaginal bleeding or discharge not related
to menstruation, bleeding after menopause, difficult or painful urination, pain during
sexual intercourse, and pelvic pain (NCI, 2020b). Tests used for diagnosis of uterine
cancer are biopsy, dilation and curettage, hysteroscopy, physical exam, review of health
history, and transvaginal ultrasound. A pap smear test is not recommended for this type
of cancer because endometrium cancer begins in the uterus and does not appear in the
results of a pap test (NCI, 2020b). Prognosis and treatment options depend on staging of
cancer, microscopic evaluation of the cell growth, and if cancer cells are affected by
progesterone. Staging for uterine cancer includes Stage I, Stage II, Stage III, and Stage IV
and grouped for treatment as low-risk cancer or high-risk cancer (NCI, 2020b). See
Figure 2 for staging and treatment options.
Ovarian, Fallopian, and Peritoneal Cancer
Ovarian, fallopian, and peritoneal cancer occurs when malignant cells are in the
tissues that cover the ovaries, lining of the fallopian tubes, and peritoneum. Since these
three types of cancers all form in the same types of tissue, they are all treated in the same
manner (NCI, 2020c). The ovaries are a paired organ in a woman’s reproductive system.
They are about the size of an almond and positioned on both sides of the uterus. The
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ovaries are responsible for producing eggs, called the ova or oocytes, and hormones.
Other types of cancers affecting the ovaries include ovarian germ cell tumors, ovarian
low malignant potential tumors, and childhood ovarian cancer treatment (NCI, 2020c).
The fallopian tubes are a pair of tubes located on the sides of the uterus. Eggs from the
ovaries pass through these tubes to the uterus (NCI, 2020c). The peritoneum is the tissue
that lines a woman’s abdominal wall and covers organs located in the abdomen. Cancer
that forms in the peritoneum and has not metastasized is regarded as primary peritoneum
cancer, however, cancer can begin in the peritoneum and metastasize to one or both
ovaries (NCI, 2020c). Risk factors for women developing ovarian cancer consist of
family history, BRCA1 or BRCA2 genes, hereditary conditions such as hereditary
nonpolyposis colorectal cancer (HPNCC) or Lynch Syndrome, endometriosis, HRT,
obesity, taller than average height, and age. According to the (NCI, 2020c), 20% of all
ovarian cancer cases are caused by hereditary ovarian cancer. Women with an increased
risk of developing ovarian cancer may choose a prophylactic oophorectomy, surgical
removal of the ovaries, subsequently reducing cancer growth and lessening risk for future
disease. In women who are identified as high-risk of developing ovarian cancer this
procedure has been confirmed to considerably reduce their risk of developing ovarian
cancer (NCI, 2020c). Unfortunately, there are no early signs and symptoms for ovarian,
fallopian, and peritoneal cancer. When signs and symptoms are present, the cancer is
likely in an advanced stage. These latent signs and symptoms include pain, swelling, or
pressure in the abdomen or pelvis, sudden or frequent urge to urinate, trouble with eating
and satiety, lump in pelvic area, and gastrointestinal problems such as gas, bloating, and
or constipation (NCI, 2020c). Diagnostic testing involves a physical exam, review of
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health history, pelvic exam, and a CA 125 assay (a blood test that measures the amount of
CA 125 protein, in the blood). This test detects early signs of ovarian cancer in people
who are at a high risk of developing this disease (Mayo Clinic, 2020). Other diagnostic
tests for ovarian cancer included, ultrasound examination, Computer Tomography Scan
(CT scan), Position Emission Tomography scan (PET scan), Magnetic Resonance
Imaging (MRI), chest x-ray, and biopsy. Prognosis and treatment for women diagnosed
with ovarian, fallopian, and peritoneum cancer depends on the type and how invasive the
cancer is; stage and grade, fluid in the abdomen, if all the tumor can be removed by
surgery, changes in BRCA1 or BRCA2 genes, age, health of the patient, new diagnosis, or
recurrent cancer (NCI, 2020c). Staging for ovarian, fallopian, and peritoneum cancer
includes Stage I, Stage II, Stage III, and Stage IV. See Figure 2 for staging and treatment
options.
Vaginal Cancer
Vaginal cancer is a disease where malignant cells form in the vagina. The vagina
is the canal from the cervix to the outside of a woman’s body. During birth, a baby moves
through the vagina or birth canal out of the body (NCI, 2020d). Vaginal cancer is rare and
has been hard to study. There are no “standard” treatments that experts agree on. Most
experts agree that treatment in a clinical trial should be considered for any type or stage
of vaginal cancer (ACS, 2020a). There are two types of vaginal cancer: Squamous cell
carcinoma and adenocarcinoma. Squamous cell carcinoma is the most common type of
vaginal cancer and develops in the lining of the thin, flat lining cells of the inside of the
vagina. This type of cancer can metastasize very slowly and usually stays close to the
vagina; however, it can metastasize to the lungs, liver, or bone. Adenocarcinoma begins
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in the granular cells; these cells create and release mucus in the vagina. This type of
cancer is more prone to metastasize to the lungs and lymph nodes (NCI, 2020d). A rare
type of adenocarcinoma known as clear cell adenocarcinoma is linked to women being
exposed to DES in utero. Risk factors for women developing vaginal cancer include
being 60 years of age or older, HPV, DES, and past hysterectomy for benign or malignant
cancer (NCI, 2020d). Unfortunately, there are no early signs and symptoms for vaginal
cancer, it may be found during a routine pelvic exam and pap smear test. Signs and
symptoms of vaginal cancer involve bleeding or discharge not related to menstruation,
pain during sexual intercourse, pain within the pelvic area, lump in the vagina, pain
during urination, and constipation (NCI, 2020d). Diagnostic testing involves physical
exam, review of health history, pelvic exam, pap smear test, HPV test, colposcopy, and
biopsy. Prognosis and treatment for vaginal cancer depends on the stage of the cancer,
metastasis, size, grade, location of the cancer within the vagina, signs and symptoms, and
new diagnosis or recurrent cancer (NCI, 2020d). Treatment for vaginal cancer depends on
staging and size, if the cancer is located near other organs that can be compromised by
treatment, if the tumor is squamous cell or an adenocarcinoma, history of hysterectomy,
and history of radiation to the pelvis. Stages for vaginal cancer included Stage I, Stage II,
Stage III, Stage IV, and recurrent cancer (NCI, 2020d). See Figure 2 for staging and
treatment.
Vulvar Cancer
Vulvar cancer is a rare disease where malignant cells develop in the tissue of the
vulva. The vulvar area includes the inner and outer lips of the vagina, clitoris, opening of
the vagina and its glands, mons pubis, and the perineum (NCI, 2020e). Risk factors for
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this type of cancer include one or more of the following: Vulvar Intraepithelial Neoplasia
(VIN), HPV, older age, genital warts, multiple sexual partners, first sexual intercourse
experience at a young age, and abnormal pap smear tests (NCI, 2020e). Signs and
symptoms of vulvar cancer can include a lump or growth that looks like a wart or ulcer
on the vulva, itching that does not go away, bleeding not related to menstruation, and
pain (NCI, 2020e). Tests and procedures that are used to diagnose and examine vulva
cancer included physical exam, review of health history, pelvic exam, pap smear test,
HPV test, biopsy, colposcopy, MRI, CT scan, and PET scan (NCI, 2020e). Prognosis for
women diagnosed with vulvar cancer and treatment options depend on if the cancer has
metastasized to other tissues, lymph nodes, new diagnosis, or recurrent cancer (NCI,
2020e). Stages of vulvar cancer include Stage I, Stage II, Stage III, Stage IV, and
recurrent. See Figure 2 for staging and treatment options.
Gestational Trophoblastic Disease
Gestational trophoblastic disease (GTD) is a group of rare diseases where
abnormal trophoblast cells grow inside of the uterus after conception (NCI, 2020f).
These trophoblast cells normally surround a fertilized egg in the uterus and help to
connect the fertilized egg to the wall of the uterus and form part of the placenta (NCI,
2020f). However, sometimes there is a problem with the fertilized egg and trophoblast
cells. Instead of a fetus developing, a tumor forms. Most GTD is benign and does not
spread, but some types may become malignant and metastasize (NCI, 2020f). GTD can
be categorized into two types: Hydatidiform Moles (HM) and Gestational Trophoblastic
Neoplasia (GTN). HM is the most common type of GTD also knowns as molar
pregnancy. HM is a slow growing tumor and can be complete HM or partial HM. A
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complete HM form is when sperm fertilizes an egg that does not contain the mother’s
DNA. The cells that were meant to become the placenta are abnormal (NCI, 2020f). A
partial HM occurs when sperm fertilizes a normal egg and there are two sets of DNA
from the father in the egg. Only part of the fetus forms and the cells that would have
become the placenta are abnormal (NCI, 2020f). Risk factors that a HM will develop into
cancer include: pregnancy before 20 or after 35 years of age, a high level of beta human
chorionic gonadotropin (β-hCG), a large tumor in the uterus, an ovarian cyst larger than
six centimeters, hypertension during pregnancy, hyperthyroidism, hyperemesis
gravidarum, trophoblastic cells in blood, and serious blood clotting problems (NCI,
2020f). GTN includes invasive moles, choriocarcinomas, placental-site trophoblastic
tumors (PSTT), and epithelioid trophoblastic tumor (ETT). Risk factors for developing
GTD are pregnancy before 20 years of age or after 35 years of age and having a personal
history of HM. Signs and symptoms include: vaginal bleeding not related to
menstruation, large uterus during pregnancy, pain or pressure in pelvis, hyperemesis
gravidarum, hypertension with headache and swelling of the feet and hands during early
pregnancy, longer than normal vaginal bleeding that continues after delivery, fatigue,
shortness of breath, dizziness, and fast or irregular heartbeat caused by anemia (NCI,
2020f). Diagnostic testing for GTD includes a physical exam, pelvic exam, blood sample,
and urinalysis. GTD can usually be cured, however, treatment and prognosis depend on
type, metastasis, number of tumors, size of the tumor, level on β-hCG in the blood,
timing of diagnosis after pregnancy began, whether GTD occurred after a molar
pregnancy, miscarriage, or normal pregnancy, and previous treatment for GTN (NCI,
2020f). Diagnostic staging for GTN may include chest x-ray, CAT scan, MRI with

PILOT STUDY of OHRQoL DURING GYN CANCER TREATMENT

13

gadolinium, and lumbar punction. Stages for GTN are Stage I, II, III, and IV (NCI
2020f). See Figure 2 for staging and treatment. There is no staging for HM.
Figure 2
Staging and Treatment Therapies
Type of
Cancer

Stage

Cervical

Carcinoma
in Situ

During
pregnancy

Therapies
Surgery

Chemotherapy

Laser surgery
Hysterectomy

Radiation

Other

Internal radiation
therapy for
women who
cannot have
surgery

Cold knife
conization

Carcinoma
in Situ

Loop
electrosurgical
excision
(LOOP)
No treatment
during
pregnancy
Colposcopy
may be done
to check for
invasive
cancer

IA1

Total
hysterectomy
with or without
bilateral
salpingooophorectomy

IA2

Modified
radical
hysterectomy
and removal of
lymph nodes

Conization

Internal radiation
therapy for
women who
cannot have
surgery

Clinical trials

Radical
trachelectomy
During
pregnancy

I

Radical
trachelectomy

IB, IIA

Radical
hysterectomy
and removal of

Conization
Chemotherapy

Radiation
therapy to pelvis
after

Clinical trials
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pelvic lymph
nodes
Radical
trachelectomy
IIB, III,
IVA

Removal of
pelvic lymph
nodes followed
by radiation
therapy with or
without
chemotherapy

IVB

Chemotherapy
followed by
surgery

hysterectomy or
alone

Chemotherapy
with radiation at
the same time

Internal radiation
therapy

II, III, IV

Chemotherapy
and targeted
therapy

Recurrent

After delivery

Pelvic
exenteration

Clinical trial
chemotherapy
followed by
surgery
Clinical trial of
chemotherapy
and radiation
therapy given
at the same
time followed
by
chemotherapy

Radiation
therapy as
palliative therapy
improve QoL

Clinical trials
of new
anticancer
drugs or drug
combinations

Chemotherapy in
second or third
trimester

After delivery

Termination of
pregnancy
before
treatment
begins

Chemotherapy

Radiation

Chemotherapy as
palliative therapy
to improve QoL
During
pregnancy
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Chemotherapy
with target
therapy
Chemotherapy
was palliative
therapy to
improve QoL

Radiation plus
chemotherapy

Clinical trials
of new
anticancer
drug or drug
combination
Immunetherapy
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Uterine

I, II (Low
risk)

Total
hysterectomy
and bilateral
salpingooophorectomy

Alone for
patients who
cannot have
surgery

15
Clinical trial

Internal radiation
or external
radiation after
total
hysterectomy
and bilateral
salpingooophorectomy
with or without
removal of
lymph nodes

Total
hysterectomy
and bilateral
salpingooophorectomy
with or without
the removal of
lymph nodes in
pelvis and
abdomen
If spread to
cervix, radical
hysterectomy
with bilateral
salpingooophorectomy
I, II (high
risk)

Radical
hysterectomy
and bilateral
salpingooophorectomy
lymph lodes in
pelvis and
abdomen may
be removed and
viewed for
cancer cells

After radical
hysterectomy and
bilateral salpingooophorectomy

Sometimes after
radical
hysterectomy
and bilateral
salpingooophorectomy
and
chemotherapy

Clinical trial

III, IV,
recurrent

Radical
hysterectomy
and removal of
lymph nodes in
pelvis viewed
for cancer cell

Adjunct
chemotherapy
after radical
hysterectomy and
removal of lymph
nodes in pelvis
viewed for cancer
cell

And/or radiation
therapy after
radical
hysterectomy
and removal of
lymph nodes in
pelvis viewed for
cancer cell and
chemotherapy

Hormone
therapy
(patients who
cannot have
surgery)

Chemotherapy
and internal and
external radiation
(patients who
cannot have
surgery)

Targeted
therapy with
MTOR
inhibitors
(everolimus or
ridaforolimus)
or a
monoclonal
antibody
(bevacizumab)
Clinical trials
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Ovarian,
fallopian
tube, and
primary
peritoneal

I (early)

Debulking for
stage

16

After surgery

Hysterectomy
with bilateral
salpingooophorectomy
omentectomy
lymph nodes
Other tissues
from pelvis and
abdomen
unilateral
salpingooophorectomy
for women who
wish to have
children
II, III, IV
(Advanced)

Debulking for
stage
Hysterectomy
with bilateral
salpingooophorectomy
Omentectomy
Lymph nodes
other tissues
from pelvis and
abdomen

Intravenous (IV)
Intraperitoneal
(IP)
With targeted
therapy
(bevacizumab)

Targeted
therapy with
PARP
inhibitor
(alaparib,
rucaparib,
niraparib)
Clinical trial

Targeted therapy
with a poly (ADPribose)
polymerase
(PARP) inhibitor
Targeted therapy
followed by
surgery possibly
followed by IP
chemotherapy
Alone (patients
who cannot have
surgery)

Recurrent

Using one or
more anticancer
drugs

And/or target
therapy
(bevacizumab)

Targeted
therapy with a
poly (ADPribose)
polymerase
(PARP)
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inhibitor
(Olaparib,
rucaparib, or
niraparib) with
or without
chemotherapy
Clinical trial

Vaginal

Vaginal
intraepithelial
neoplasia
(VAIN)

Pre-cancerous
change in cells
go away on
own
watched by
doctor
pap tests
colposcopy

VAIN 2

Removal of
lesion or
abnormal cells

Intracavitary
radiation
(brachytherapy)

Topical
therapy (5 -FU
or imiquimod)
Laser
treatment

0 (VAIN 3
or
carcinoma
in Situ
[CIS])

Local excision

I

Partial or
radical
vaginectomy

Intracavitary
radiation
(brachytherapy)

If cancer comes
back, partial
vaginectomy

Radical
hysterectomy
Bilateral
radical pelvic
lymph node
removal and/or
radical or
partial
vaginectomy

Cancer < 5mm
thick (3/16 inch)
intracavitary
radiation used
alone
Tumors grown
more deeply
intracavitary
radiation maybe
combined with
external beam
radiation

Laser
vaporization
Topical
therapy 5-FU
cream or
imiquimod 10
weeks
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II

Radical
vaginectomy
Pelvic
exenteration

With radiation
To shrink cancer
before radical
surgery

18

Brachytherapy
and external
beam radiation

III or IVA

Combined with
radiation

Brachytherapy
and external
beam radiation

IVB

Combined with
radiation
Alone QoL

To vagina and
pelvis to ease
symptoms reduce
bleeding

live longer

QoL

Clinical trial

Recurrent
Local
(comes
back in
same place)

Pelvic
exenteration

Brachytherapy
and external
beam

Stage I, II
Distant
(comes
back in
another
part of the
body)

Relieving
symptoms
palliative care
Clinical trial

Surgery

Chemotherapy

Radiation

Clinical trial
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Vulvar

Vulvar
Intraepithelial
Neoplasia
(VIN)

Separate
excision of
lesions

19
Immunotherapy with
topical
imiquimod

Wide local
excision
Laser surgery
Ultrasound
surgical
aspiration
Skinny
vulvectomy

I, II

Wide local
excision
Radical local
excision with
removal of
lymph nodes in
groin and upper
thigh

After modified
or radical
vulvectomy
After radical
local excision
Alone

Modified
radical
vulvectomy
Radical
vulvectomy
with removal of
lymph nodes in
groin and upper
thigh
Radical local
excision and
removal of
sentinel lymph
node
III

Modified
radical
vulvectomy
Radical
vulvectomy
with removal of
lymph nodes in
groin and upper
thigh with or

Alone or
combined with
chemotherapy
and then
followed by
surgery

Clinical trial
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without
radiation
IVB

Recurrent

Maybe used if
patient can
tolerate it
Wide local
excision with or
without
radiation
therapy
Radical
vulvectomy and
pelvic
exenteration

Chemotherapy
with radiation
with or without
surgery

No standard
treatment
Clinical trial
With or without
chemotherapy
And surgery
Palliative
treatment to
relieve
symptoms and
improve QOL

Clinical trial
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GTD

HM

Dilation and
curettage to
remove tumor

If disease remains
after surgery

21
Blood test
done every
week until βhCG level
returns to
normal.
Monthly
follow up
visits up to six
months

GTN

With one or more
anticancer drugs
until β-hCG level
is normal for at
least three weeks
after treatment.

low-risk

If β-hCG does not
return to normal
or metastasis
chemotherapy
regimens for highrisk GTN is given
Combination
chemotherapy

GTN
high-risk

PSGTT &
ETT

Clinical trial

Intrathecal
chemotherapy and

radiation to the
brain (cancer
spread to lungs)

High-dose
chemotherapy
and/ or intrathecal
chemotherapy

and/or radiation
therapy to the
brain (cancer that
spread to brain)

Remove uterus

Clinical trial

Stage I
Stage II

Remove the
tumor

Combination
chemotherapy

Clinical trial

Stage

Surgery to
remove
metastasized
cancer

Combination
chemotherapy

Clinical trial

III, IV
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Recurrent
or resistant
GTN

Surgery

Chemotherapy
with one or more
anticancer drugs

22
Clinical trial

Combination
chemotherapy

Note. From “Cervical Cancer Treatment (PDQ)-Patient Version,” “Uterine Cancer
Treatment (PDQ)-Patient Version,” “Ovarian, Fallopian, and Peritoneal Cancer
Treatment (PDQ) - Patient Version,” “Vaginal Cancer Treatment (PDQ) - Patient
Version,” “Vulvar Cancer Treatment (PDQ) – Patient Version,” Gestational
Trophoblastic Disease (PDQ) – Patient Version,” by National Cancer Institute, May 2020
The NIDCR (2009) estimates that 40% of patients receiving cancer treatment
therapy are at risk of oral complications. The NIDCR, recommends seeing a dentist at
least one month before starting chemotherapy and/or radiation therapy. With this
proactive approach, the dentist, dental hygienist, and dental therapist can treat existing
dental complications and provide palliative care as the patients’ oncology treatment
progresses, thereby, minimizing the patients’ chance of serious oral complications.
Interprofessional care involves the patient’s dentist, dental hygienist, dental therapist, and
oncologist working together on a custom home-care routine personalized for each patient
and their specific condition.
Pretreatment Oral Care
First, a pretreatment oral assessment of the patient should be performed.
Comprehensive patient education plays a central role, and a standard oral care protocol
should be applied (Saadeh, 2005). Collective studies suggest the use of a systematic
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protocol improves patient outcomes (Rubenstein et al., 2004). Preventive oral health care
should be strongly emphasized along with oral hygiene instruction and education
emphasizing the importance of effective plaque removal and regular dental visits to
support oral health. A comprehensive oral care plan should include oral hygiene
strategies that may change throughout the stages of oncology treatment(s). At this
pretreatment visit, patients should have a thorough dental examination that includes
examination of hard and soft tissues, radiographs, periodontal and dental charting to
detect infections and pathology. Diagnosis and treatment of infections and, dental caries,
and oral prophylaxis if indicated should be completed. Patients should be counseled on
tobacco cessation, limiting alcohol intake, nutritional intake, effective oral hygiene
practices, and early detection of oral lesions to reduce the onset of two to three weeks
before initiating chemotherapy. Antibiotic prophylaxis is also necessary if granulocytes
are under 2,000/mm3 noted from a blood screening. Moreover, limited invasive
procedures should take place at least two-weeks before the start chemotherapy.
Prevention and management can greatly reduce the risk of secondary oral diseases and
minimize any decline in the patient’s QoL (Rhodes-Nesset & Laronde, 2014). See Table
1 for oral hygiene care guidelines for patients to follow before beginning cancer
treatment.
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Table 1
Oral Hygiene Care for Patients Before Beginning Cancer Treatment
General Guidelines
• Plaque removal is performed with an extra-soft nylon bristle toothbrush and
gentle flossing so as not to cause trauma.
• Recommend products that are easy to grasp and manipulate (floss handle, power
toothbrushes).
• Prescribe a 5000-ppm fluoride toothpaste/gel to reduce the risk of dental caries.
Recommend products for topical management of xerostomia and oral lesions.
Specific Mucositis/Stomatitis Guidelines
• Suggest patient suck on ice chips for 39 minutes before and during chemotherapy
to keep the oral cavity moist.
• Recommend patients rinse with an alkaline saline mouth rinse that includes ½
teaspoon of baking soda and ½ teaspoon of salt in 16 ounces of water. Patients
should rinse at least five times per day.
Note. From “Oral health maintenance for patients with breast cancer,” by Taichman and
Tindle., 2016, The Journal of Multidisciplinary Care Decisions in Dentistry. Copyright
by 2016 The Journal of Multidisciplinary Care Decisions in Dentistry.
Oral Complications and Therapies During Cancer Treatment
Treatment for cancer typically involves surgery, chemotherapy, radiation and/or a
combination of all three. Even with the encouraging evolvement in cancer management
over the past decades, one should bear in mind that current treatment modalities do have
the potential to result in devastating and sometimes deadly adverse effects that not only
decrease the patients’ QoL but also increase their morbidity and mortality. Chemotherapy
can be associated with numerous side effects that can affect the patient’s QoL.
Unfortunately, the risk benefit ratio in oncology therapy results in most of these side
effects being unavoidable. Several preventive measures are taken in order to limit their
expression. Nevertheless, most oncology patients experience difficult situations in
managing oral side effects and complications of oncology therapies. See Table 2 for
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symptoms and therapies that alleviate complications that may occur from cancer
treatment(s).
Table 2
Oral Complications of Cancer, Symptoms, and Therapies
Complications

Symptoms

Therapies

Hyposalivation

Dry mouth, thick ropey
saliva

Saliva substitutes, sip
water, suck on ice
chips, avoid spicy
foods and alcohol,
fluoride varnish,
toothpaste, or gel to
prevent caries

Loss of sensory function

Alteration or loss of taste,
bad breath, neuropathy

Pretreatment
education

Limited opening

Pain, and /or trismus in
muscle, TMJ, neck,
shoulder

Warm compress,
physical therapy, jaw
exercises

Infection

Pain, odor, exudate,
bleeding

Antibiotics, topical
anesthetics,
analgesics for oral
pain

Mucosal changes

Mucositis, halitosis,
neuropathy, pain

Oral hygiene, ¼
baking soda and 1
quart of water
solution mouthwash
followed by plain
water rinse several
times a day, “magic
mouth wash”

Caries

Pain, lesions

Avoid candy, gum,
and soda unless they
are sugar free,
fluoride toothpaste
5000 ppm, custom
trays and fluoride gel,

25
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fluoride varnish,
xylitol products
Periodontal disease
progression

Clinical attachment loss,
mobility

Periodontal
maintenance visits

Risk of mucosal injury

Pain

Take precaution to
protect against
trauma, topical
anesthetics,
analgesics for oral
pain

Osteoradionecrosis

Pain, bad breath, non-or
slow healing soft tissue

Elective oral surgery
should not be
performed for the
duration of radiation
treatment, antibiotics,
hyperbaric oxygen
therapy

Poor esthetics

Low quality of life,
depression

New dentures or
partials may need to
be reconstructed

Trouble speaking

Social withdrawal,
depression

Jaw exercise, speech
language therapy

Trouble eating and
swallowing

Limited energy, discomfort
while eating

Pretreatment
education, soft food
diet, saliva
substitutes, hydration,
avoid spicy food and
alcohol

Note. From “Oral complications of cancer and cancer therapy,” by Epstein et al., 2012
CA: A Cancer Journal for Clinicians, 62(6), 400-422. Copyright 2012 by American
Cancer Society, Inc.
The NIDCR (2018), suggests most people are aware of the common side effects
of cancer treatment, nausea, and hair loss. However, many may not realize more than
one-third of people treated for cancer develop complications that affect the mouth. These
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complications may impede cancer treatments and diminish the patient's QoL. Radiation
and chemotherapy can lead to complications such as: mucositis, hyposalivation, poor oral
hygiene, periodontal problems, increase in dental caries, oral pain, dysgeusia (altered
taste), oral dryness, dysphagia (difficulty swallowing), and osteoradionecrosis (NIDCR,
2018). A preemptive treatment plan can promote optimal oral health and avoid or
minimize oral manifestation of complications during and beyond treatment. See Figure 3.
Mucositis. One of the unfortunate consequences of cancer therapies is the
development of painful mouth sores, known as oral mucositis. Mucositis is erythema and
ulceration of the mucosa. Oral mucositis plays a significant role in the physical and
psychosocial aspects of patients undergoing cancer therapy (Cawley & Benson, 2005).
Oral mucositis has emerged as one of the most frequent causes of treatment delay and
dosage reductions in cancer therapy and it affects patients across all treatment modalities.
Cawley & Benson’s research also concluded patients’ QoL can be affected by pain,
infection, modified nutrition, and destruction of oral function, resulting in potential
treatment delays and economic burden. The frequency of oral mucositis is about 30% 40% in the general oncology patient population (Lionel et al., 2006). Oncology patients
consider oral mucositis to be the most difficult treatment-related complication to endure.
The severity of mucositis has a direct influence on the treatment planning with the
necessity of dose reductions, delays, or even discontinuations of treatment therapy. Oral
mucositis can also promote the development of life-threatening infections such as
neutropenia, where the patient has reduced white blood cell count, significantly
increasing risk for infection (Lionel et al., 2006). Research suggests that prior to
beginning oncology treatment, all patients should visit their dental health provider for a
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thorough pre-treatment oral assessment as noted above. Comprehensive patient education
plays a central role, and a standard oral care protocol should be applied, but there is not
enough evidence to recommend one protocol over another (Saadeh, 2005). Collective
studies suggest the use of a systematic protocol improves patient outcomes (Rubenstein et
al., 2004). Some simple oral care should be suggested, for instance: brushing teeth twice
daily using a new toothbrush at each chemotherapy cycle, daily flossing, and mouth
rinsing with sterile water after brushing or flossing. In addition, spicy food, alcoholic
beverages, and alcohol-based mouthwashes should be avoided (Larson et al., 1998).
Individuals undergoing chemotherapy or radiation therapy are often advised to eat a soft
or liquid diet. Mucositis is not an infectious process; therefore, it cannot be prevented
with antibiotics or antiviral medications and cannot be passed to another person
(American Academy of Oral Medicine (AAOM), 2015).
Salivary Disfunction. Salivary gland hypofunction or hyposalivation is a
condition of having reduced saliva production which is different from xerostomia often
referred to as “dry mouth”. The best way to diagnose hyposalivation is to measure the
salivary flow. Salivary flow rates have been used as the basis for diagnosing
hyposalivation in a large-scale study. The average unstimulated whole salivary flow rate
is 0.3 – 0.4 ml/minute during waking hours. An unstimulated rate of .1ml/minute or less
indicates hyposalivation (Wiener et al., 2010). People with hyposalivation experience
inadequate bicarbonate and urea buffering, remineralization, and sugar and acid clearance
that may result in an increased caries rate (Wiener et al., 2010). Although xerostomia
often is a manifestation of impaired salivary gland function, it can occur with or without a
noticeable decrease in saliva production. In most circumstances, xerostomia is
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accompanied by salivary flow hypofunction, which reflects an objective, measurable
decrease in salivary flow (hyposalivation). Symptoms of dry mouth range from mild oral
discomfort to significant oral disease that can compromise patient’s health, dietary intake,
and QoL (American Dental Association Council on Scientific Affairs [ADACSA] 2015,
p.1). Patients should receive detailed information about the potential causes of dry mouth
and the potential sequelae of impaired salivary secretion, including dental caries,
candidiasis, and mucosal complications. Preventive oral health care should be strongly
emphasized including oral hygiene instruction and regular dental visits to promote oral
health. A meticulous oral hygiene regimen to effectively remove biofilm is
recommended, including twice-daily tooth-brushing, regular use of floss or another
interdental cleaner, and use of alcohol-free mouth rinse (ADACSA, 2015, p.11). See
Table 3 for management of hyposalivation.
Table 3
Saliva Management
Management
Preventative: cancer treatment planning, amifostine
Sialagogues: (with residual function)
Viscous saliva: mucolytic agents
Excess saliva: xerostomia (anticholinergic) medications
Palliation with lack of function: mouth-wetting agents (be aware of the pH of product),
presence/absence of fluoride. Ca PO4, xylitol
Dental prevention: cariogenic microbial flora (chlorhexidine, xylitol), mineralization,
local infection.
Note. Ca PO4 indicates calcium phosphate, F, fluoride. From “Oral complications of
cancer and cancer therapy,” by Epstein et al., 2012, CA: A Cancer Journal for Clinicians,
62(6), 400-422. Copyright 2012 by American Cancer Society, Inc.
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Dental Caries. Dental caries or tooth decay is defined by the NIDCR as “damage
to a tooth that can happen when decay-causing bacteria in a person’s mouth makes acid
that attacks the tooth’s surface or enamel.” If not treated, caries can cause an infection,
pain, and tooth loss. The benefits of fluoride are well documented and topical fluoride is
considered the gold standard in the prevention of dental caries (Rhodes-Nesset &
Laronde, 2014). Fluoride increases the enamel structure’s resistance to acid, inhibits
bacteria, and re-mineralizes the tooth. During the pre-cancer dental assessment an oral
healthcare provider such as a dentist, dental hygienist, or dental therapist may use a
dental caries assessment tool, Caries Assessment Management By Risk Assessment
(CAMBRA) to assess if a patient is at a high risk for caries. The NIDCR (2009)
recommends the use of custom fluoride gel mouth trays or brush on fluoride gel that is
either a 1.1% neutral pH sodium gel or 0.4% stannous fluoride gel. The NIDCR, also
recommends the use of daily fluoride application to all patients who have hyposalivation
due to radiation.
Fungal Infections. Candidiasis is the most common fungal infection caused by
Candida albicans which is a human commensal and a major resident of the skin, mucosal
surfaces, the gastrointestinal (GI) tract and the female genitourinary tract. Candida
albicans can cause superficial disease in otherwise healthy individuals, but infection in
immunocompromised individuals can progress towards a potentially lethal systemic
form. Most studies place the crude mortality rate due to Candida albicans infections at
approximately 30% – 40% (Teoh & Pavelka, 2016). Candida albicans is one of the
leading causes of opportunistic microbial infections in cancer patients, often presenting in
a life-threatening systemic form. Increased susceptibility to such infections in cancer
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patients is attributed primarily to chemotherapy-induced depression of innate immune
cells and weakened epithelial barriers, which are the body’s first-line defense against
fungal infections (Teoh & Pavelka, 2016). The most common forms of oral candidiasis
conveyed in oncology patients are pseudomembranous and erythematous candidiasis.
Hyperplastic candidiasis is rarely reported (Lalla et al., 2008). Lalla et al. (2008) report
the prevalence of oral fungal infection from all forms of cancer therapy: 7.5% before
treatment, 40% during treatment, and 30% after treatment. Pseudomembranous
candidiasis may be accompanied by burning pain, taste changes when eating, and a foul
taste when not eating. Erythematous candidiasis is often associated with a burning
sensation of the mouth. Involvement of the dorsal tongue may lead to a diffuse loss of
filiform papillae, leading to a “bald” and red appearance, often accompanied by
discomfort and taste changes. Angular cheilitis, inflammation often caused by Candida
albicans infection in the corners of the lips is, often uncomfortable and may cause pain
when opening the mouth wide. Thus, the symptoms of oral candidiasis can have a
significant impact on QoL and hinder nutritional intake. In addition, immunosuppressed
oncology patients are at higher risk for oral candidiasis to spread throughout the
oropharyngeal regions and subsequently to the systemic circulation (Lionel et al., 2006).
Therefore, oral candidiasis can influence systemic outcomes of oncology therapy. Oral
candidiasis is easily treated in the early stages. Early recognition and treatment are
particularly important in oncology patients. However, there is limited information on the
prevalence of oral fungal infection in gynecologic oncology population and its impact on
QoL. The Infectious Diseases Society of America (IDSA), 2009 guidelines recommend
the use of topical clotrimazole troches or nystatin as a first-line therapy for the
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management of mild oropharyngeal candidiasis (OPC) and the use of systemic
fluconazole for moderate to severe OPC.
Viral Infections. During cancer treatment, a patient may have oral reactivation of
latent Herpes Simplex Virus (HSV) infections. Viral reactivation can cause oral mucosa
damage, worsen already existing lesions caused by stomatotoxic effects of cancer therapy
and, whether symptomatic or asymptomatic, sufficient spreading and promoting of viral
transmission (Djuric et al., 2009). There are two types of HSV. Herpes Simplex Virus
type 1 is mainly transmitted by oral to oral contact to cause symptoms known as “cold
sores” but it can also cause genital herpes. Herpes Simplex Virus type 2 is a sexually
transmitted infection that causes genital herpes (WHO, 2020). Infection with HSV type 1
can cause orofacial lesions with pain and blistering on or around the lips and within the
mouth. Recurrent HSV type 1 infection in patients who are immunocompromised due to
treatment for cancer may be more aggressive, painful, and slower to heal. These more
extensive HSV lesions often require much longer treatment and leave the patient more
susceptible to developing drug-resistant strains of HSV (Glenny et al., 2009). People with
active symptoms of herpetic lesions should avoid oral contact with others and sharing
objects that have contact with saliva. They should also abstain from oral sex to avoid
transmitting HSV type 1 to the genitals of a sexual partner. Individuals with symptoms of
genital herpes, HSV type 2, should abstain from sexual activity while experiencing any
symptoms (WHO, 2020). Recurrent symptoms of genital herpes HSV type 2 may be
painful, and the infection can lead to social stigma and psychological distress. These
factors can have an important impact on QoL and sexual relationships. With time, most
people with HSV type 2 adjust to living with the infection. Treatment for HSV type 1 and
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type 2 include antivirals, such as acyclovir, famciclovir, and valacyclovir, and are the
most effective medications available for people. These antiviral drugs can help to reduce
the severity and frequency of symptoms but cannot cure the infection (WHO, 2020).
Gingivitis. Gingivitis is assessed by gingival erythema and bleeding on probing in
the absence of bone loss. Intraoral bleeding is another complication associated with
chemotherapy. This bleeding can be spontaneous, traumatically induced, or an effect
from existing pathology (Wong, 2014). It can also result from thrombocytopenia
secondary to hematopoietic tissues suppression. Laboratory tests should be used to assess
bleeding potential. Thrombocyte count and bleeding time can give the dentist a clear
picture of the quantity, quality, and function of platelets (Wong, 2014). Dental calculus
removal, placement of fluoride, and chlorhexidine mouthwash are highly recommended.
Chlorhexidine provides bactericidal activity against gram-positive and gram-negative
bacteria by damaging the cell membrane and cellular enzymes. Chlorhexidine 0.12% has
been found to reduce bleeding and plaque accumulation, as well as a reduction in
Streptococcus mutans concentrations in saliva (Poulopoulos et al., 2017).
Periodontal Infections. The infected and inflamed periodontium can act as a
focus for systemic infection in neutropenic cancer patients. The incidence of these oral
infections is unknown, but likely underestimated. Periodontal infections can easily be
overlooked, primarily because symptoms of gingival inflammation may be minimal, and
the infection maybe located in deeper parts of the periodontium. Assessment of a patient's
periodontal condition before the onset of profound neutropenia is critical to the diagnosis
and the management of these potentially life-threatening infections (Raber-Durlacher et
al., 2002). Research conducted by Vozza et al. (2014) studied the incidence of
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periodontal disease in cancer patients (N = 54). All patients received oral hygiene
instructions and the diseased patients received periodontal treatment at baseline. The
prevalence of periodontitis was (n = 19) 35.2% at baseline and no significant difference
was found in the follow‐up assessments. There was a statistically significant reduction in
probing depth (PD), plaque index (PI) and bleeding on probing (BOP). The attachment
level (AL) did not vary significantly between the different follow‐up periods (p ≥ 0.06).
Comparisons between the groups were performed using the McNemar test (p > 0.05) and
the Wilcoxon test with Bonferroni correction (p < 0.02) using SPSS software. They
concluded periodontal treatment was effective in reducing PI, BOP and PD and in
maintaining AL in periodontitis cancer patients undergoing chemotherapy (Vozza et al.,
2014). Pretreatment preventive periodontal and dental therapies are especially important
aspects in treating the oncology patient. Diagnosis, treatment, and establishment of
regular maintenance protocols are essential in treatment of periodontal disease through
neutropenic periods and to prevent excessive oral bacterial changes (Decker et al., 2018).
During treatment, it is recommended that periodontal maintenance should be continued in
oncology patients in combination with good oral hygiene. Communication between oral
care providers and oncologists is crucial for the dental treatment of cancer patients
(Decker et al., 2018). Post cancer treatment, periodontal maintenance should be
continued with careful and continuous evaluation of patients’ periodontal and dental
status.
Taste Dysfunction. The sense of taste is responsible for the detection and
ingestion of food to cover energetic requirements in health and disease. A change in taste
perception (dysgeusia) might lead to malnutrition, one of the frequent causes of
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morbidity and mortality in patients with cancer. Similarly, dysgeusia may impair the QoL
by affecting appetite, body weight, and psychological well-being (Murtaza et al., 2017).
Dysgeusia in cancer patients is usually ignored by clinicians as this aspect does not
represent the life-threatening events (Murtaza et al., 2017). In a study conducted on
cancer patients undergoing chemotherapy, the prevalence of dysgeusia was reported to be
as high as 69.9%, and a significant association was found between dysgeusia and a
change in patient's QoL such as appetite and fatigue (Murtaza et al., 2017). It was
suggested changes occurred both in the primary gustatory sense as well as in food
perception in these patients. Research also indicates precancer treatment counseling
should prepare patients’ mentally for taste alterations that may occur during oncology
treatment. This research supports the importance of pre-treatment education and
demonstrates that if a patient is prepared psychologically for dysgeusia, they can tolerate
taste changes easily and improve QoL (Rhodes- Nesset & Laronde, 2014). A close
contact and relationship between health care professionals and patients is highly desirable
to assess the nutritional status and improve the QoL of the patients (Murtaza et al., 2017)
Loss of Appetite. Loss of appetite is common in cancer patients, especially those
with ovarian, lung, stomach, or pancreatic cancer (Cancer Treatment Centers of America,
2020). Loss of appetite is a frequent side effect of chemotherapy, radiation, and
immunotherapy drugs. Loss of appetite is characterized by a diminished desire for food
or to eat food thus a loss of weight often occurs. As noted by Murtaza, et al; loss of body
weight may impair QoL.
Osteoradionecrosis. Osteoradionecrosis (ORN) is categorized by a nonhealing
area of exposed bone at least six months after a patient has been treated with radiation
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therapy. This debilitating condition is accompanied by pain and morbidity and, in
advanced stages, usually requires surgical resection and reconstruction of the affected
area (Peterson et al., 2009). Osteoradionecrosis develops as irradiation reduces the bone’s
ability to withstand trauma, avoid infection, and can be facilitated by poor nutrition and
oral hygiene (The Oral Cancer Foundation, 2020). Viswanathan et al., (2014) concluded
that gynecologic oncology patients who receive high dose radiation (HDR), specifically
those treated with interstitial brachytherapy to the distal vagina, may be at greater
probability for vaginal necrosis. Further conclusions included radiation to bone, such as
pathologic fractures, osteoradionecrosis, and second malignancies, are associated with a
decrease in QoL and increase in mortality (Viswanathan et al., 2014).
Research by Fehm et al. from the University of Teubingen Department of
Gynecology and Obstetrics from April 1999 to May 2006 found that n = 10 of 345
(2.9%) of patients with breast cancer or gynecological malignancies developed
osteonecrosis of the jaw (ONJ) during treatment while receiving bisphosphonate therapy.
Six of the ten patients with ONJ had recently had a dental procedure. Results showed that
time and exposure to bisphosphonates and the number of therapy cycles were significant
risk factors for patients developing ONJ (p < .001). Patients who did develop ONJ had a
mean number of bisphosphonate treatment cycles of 27 ±18 cycles. Patients who did not
develop ONJ had a mean bisphosphonate treatment cycle of 12 ± 12 cycles. Fehm et al.
concluded that time, dosage exposure, and the number of therapies with bisphosphonates
are the greatest risk factors for breast and gynecologic oncology patients to develop ONJ
followed by dental procedures.
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Given the risk of oral complications as noted previously, it is important for the
patient to maintain good oral hygiene throughout their cancer treatment and beyond. Oral
assessment prior to and during active treatment (chemotherapy and radiotherapy), and
following therapy is a critical aspect of oral health care for oncology patients (Taichman
et al., 2015). Pretreatment oral health education for oncology patients is crucial in
managing and potentially preventing the previously noted oral complications that are
often manifested in the oncology patient during treatment (Taichman & Tindle, 2016).
Because the oral cavity is a usual site of discomfort and pain caused by chemotherapy, an
oral care provider’s contribution to a patient’s relief is extremely important (Poulopoulos
et al., 2017). Due to a diminished immune response in oncology patients, the risk of
infection due to oral complications is greater. Therefore, maintaining good oral hygiene
and open communication with dentist, dental hygienist, dental therapist, and oncologist
about any symptoms that arise is important (University of Texas MD Anderson Cancer
Center, 2020).
Gynecologic Cancer Management Team
According to the American Dental Hygienists’ Association (ADHA, 2016) the
dental hygienist plays an integral role in assisting individuals and groups in achieving and
maintaining optimal oral health. Dental hygienists provide educational, clinical, and
consultative services to individuals and populations of all ages in a variety of settings and
capacities. They play a beneficial role in providing periodontal therapy, oral health
education, and supportive care for cancer patient(s). Dental hygienists often serve as
primary oral health care providers for women and men undergoing cancer therapy. As
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prevention specialists, dental hygienists are in a strategic position to provide information
and care to those undergoing therapy for cancer.
Research shows collaboration and communication with both the patient and the
patient’s oncologists to determine current blood work and health status prior to dental
hygiene treatment are critical. When chemotherapy has been used, the dental hygienist
needs to be aware of the patient’s immunosuppression levels by reviewing current blood
work reports. Collaboration with the patient’s oncologist is essential to ensure that it is
safe to deliver dental hygiene therapy to this group of patients (Rhodes-Nesset &
Laronde, 2014). The NIDCR, (2009) indicates an oral evaluation is necessary prior to
cancer therapy for the identification of any outstanding dental needs that could increase
the risk or severity of oral complications during cancer treatments. For patients
undergoing chemotherapy, communication between the oncology and dental teams is
essential for the safety of the patient (Taichan et al., 2015). There is a need for
interprofessional collaboration between the dentist, dental hygienists, dental therapist,
and oncologist. Collaboration and communication with other members of the
multidisciplinary team can have a significant influence on the treatment and prevention of
complications in the oral cavity (Toth et al., 1995). Because it is a team effort in
managing oncology patients, it is also equally important for dental practitioners to
communicate with medical practitioners and the patients to determine optimal managing
plans for these patients in an individual basis (Moeintaghavi et al., 2013)
Summary
The reviewed literature suggests there are benefits to oral health education on
OHRQoL prior to oropharyngeal, breast, and head and neck cancer treatments. However,
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research lacks information pertaining strictly to gynecologic cancer treatments and the
effects on patient’s oral cavity thus affecting OHRQoL. Implementing gynecological
cancer patient communication, education, and QoL concerning oral health changes during
cancer treatments maybe improved through oral health education, however more research
is needed.
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Methodology
Research Method or Design
This pilot study was conducted at the Women’s Cancer Center of Nevada (WCC)
in Las Vegas, Nevada. The Oral Health Impact Profile (OHIP-14) survey (see Appendix
A) was used to assess OHRQoL in gynecologic cancer patients pre and post dental health
education. The Oral Health Impact Profile (OHIP-14) is the most widely used QoL
measure to evaluate the influence of oral diseases on individuals (Lowal et al., 2014). The
OHIP-14 is a suitable subjective indicator that provides information about the impacts of
oral conditions on an individual’s life and perceived need for dental treatment (Husain
and Tatengkeng, 2017). The Principal Investigator (PI) recognized the benefits of face-toface education, however, because of COVID-19, the PI chose to provide all participants
with oral health educational packets that included oral health material specific to cancer
therapy, oral health home care tools (extra soft toothbrush, floss, and sensitive
toothpaste), and the PI’s personal contact information if participants had questions or
concerns. Pre-test and demographic surveys (see Appendix A and B) were given to all
participants during their appointment with their oncologist during the weeks of
2/23/2021- 3/12/21. A four-week post-test survey (see Appendix A) was emailed to all
participants via SurveyMonkey to the provided email. Initial recruitment and survey data
collection took place 3/01/21- 3/15/21 and four-week post-test surveys were emailed
3/22/21- 4/5/21.
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Procedures
The PI used a survey method approach by using the OHIP-14 to gather data and
answer research questions. Oncologists at the WCC recruited gynecologic oncology
patients who fit the inclusion criteria, collected signed consent forms, provided
participants with oral health dental educational packets, and collected pre-test surveys
during February and March 2021. Post-test surveys were emailed four-weeks later by the
PI. Survey data was organized and analyzed using Microsoft Office Excel Differences
were considered significant when p < 0.05. Data was imputed into an Excel spreadsheet
and analyzed using a paired t-test.
Human Subjects Protection/Informed Consent
The PI obtained approval from the Eastern Washington University (EWU)
Institutional Review Board (IRB) and informed consent (see Appendix C) from each
participant before the study was implemented. Participation in this study was completely
voluntary and all participants had the right to withdraw from the study at any time. To
ensure confidentiality, data was stored on the PI’s personal password and facial
recognition personal computer all hard copy data was stored in a personal non
transportable safe. To further ensure anonymity, participants were instructed to create a
research ID by selecting their favorite color and three numbers (E.g.: Pink123). After pretest surveys were completed, participants were instructed to place all material into a selfsealing envelope; envelopes were secured in a locked drawer in the manager’s office at
the WCC until the PI could collect them. The PI collected completed envelopes on
2/23/21, 3/1/21, and 3/8/21. Post-test surveys were emailed to participants four-weeks
after initial surveys were completed to the provided email. When the study concluded, all
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hard copy data was shredded and all data on PI’s laptop was transferred to a thumb drive
and stored in the PI’s personal non transportable safe for five years.
Sample source, plan, sample size, description of setting.
Participants were recruited by a convenience sample of existing WCC patients.
For pragmatic purposes, the private practice chosen was the WCC which is located in Las
Vegas, Nevada where the PI resides. This private oncology practice provided easy
accessibility to gynecologic cancer patients.
The population of this study included persons who were gynecologic cancer
patients of the WCC at the time of the study and met the minimum inclusion criteria.
Inclusion criteria included participants who had been diagnosed with a gynecologic
cancer. Participants had to be at least 18 years of age, could read, and write English, and
had access to email. Exclusion criteria included those participants who were not
diagnosed with a gynecologic cancer, were under age 18, could not read and write
English, and did not have an email address.
A cohort sampling method was employed through the WCC data base.
Participants who met the inclusion criteria were invited to participate in the study on a
volunteer basis. Patients were asked and recruited by oncologists at their scheduled
appointment. The oncologists explained the study and what it entailed. The study took
place from2/22/21- 4/5/21. Pre-test surveys and demographic surveys were collected by
oncologists and oral health dental education packets was provided to the participants.
Four-weeks after the initial surveys, a post-test SurveyMonkey link was sent via a secure
email.
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Variables
The independent variables were the oral health dental education packets,
educational reading material, and dental hygiene tools (extra soft toothbrush, fluoride
sensitive toothpaste, and floss). The dependent variables were post-test OHIP-14 scores
and OHRQoL after education was implemented.
Instruments
Quantitative data on patient OHRQoL was collected by using Slade’s 1997 shortform Oral Health Impact Profile (OHIP-14) questionnaire (Slade, 1997) (see Appendix
A). This questionnaire measures social impact of oral disorders on a person’s wellbeing.
This 14-item questionnaire is divided into seven dimensions (see Table 4); functional
limitation, physical discomfort, psychological discomfort, physical disability,
psychological disability, social disability, and handicaps (Husain & Tatengkeng, 2017).
Demographic data included age, race/ethnicity, educational experience, type of cancer,
and type of treatment(s) (see Appendix B). Participants were emailed a four-week posttest survey via SurveyMonkey to the email that was provided.
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Table 4
OHIP-14 Domains
Domain Item

Fourteen Questions

Domain 1: Functional Limitation

1. Had trouble pronouncing any words
2. Felt sense of taste has worsened

Domain 2: Physical pain

3. Had painful aching
4. Found it uncomfortable to eat any

Domain 3: Psychological
discomfort

5. Been self-conscious
6. Felt tense

Domain 4: Physical disability

7. Felt diet has been unsatisfactory
8. Had to interrupt meals

Domain 5: Psychological disability

9. Found it difficult to relax
10. Been a bit embarrassed

Domain 6: Social disability

11. Been a bit irritable
12. Had difficulty doing usual job

Domain 7: Handicap

13. Felt life less satisfying
14. Been totally unable to function

Note. From “Oral Health-Related Quality of Life Appraised by OHIP-14
Between Urban and Rural Areas in Kutai Kartanegara Regency, Indonesia: Pilot
Pathfinder Survey,” by Husain & Tatengkeng, 2017, The Open Dentistry Journal, 11,
557-564. Copyright 2017 Akbar and Tatengkeng
Equipment
Participants were provided a copy of the U. S. Department of Health and Human
Services, NIH Oncology Pocket Guide to Oral Health brochure, NIH Oncology Team
Oral Complications of Cancer Treatment: What the Oncology Team Can Do brochure,
NIH Chemotherapy and Your Mouth brochure, NIH Three Good Reasons to See a Dentist
Before Cancer Treatment PDF, Memorial Sloan Kettering Mouth Care During Your
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Cancer Treatment PDF, SurveyMonkey link for four-week post-test surveys, dental
hygiene tools that included an extra soft toothbrush, fluoride sensitive toothpaste, floss,
and the PI’s personal contact information for questions and concerns.
Steps to Implementation
After Approval from the EWU IRB the PI implemented the following steps as
outlined in Table 5.
Table 5
Steps to Implementation
Step One
Met with WCC oncologists
and medical assistants
(MA)

Step Two
Oncologists to recruit
participants:

Step Three
Implementation of study
Consent form signed

Recruit participants who
qualify during oncology
appointment

Initial surveys completed,
research ID created, and
email provided
Participants were provided
with dental education
packet which included, oral
health education material,
dental hygiene tools, and
PIs contact information

Step Five
Four-week post-test
surveys were emailed to
participants via
SurveyMonkey to provided
email address. March 22 April 5, 2021

Step Six
Statistical analysis of data
by PI of quantitative data

Discuss study topic
Educated oncologists and
MA’s on study,
participation guidelines,
and expectations for study
(see Appendix D)
Created dental health
packets
Printed educational
material
Step Four
PI collected initial surveys
and input data on personal
computer February 22 March 12, 2021
Stored hard copy data in
safe

Study concluded April 12,
2021

Excel
t-test
Pearson’s Correlation
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Summary
To evaluate all data related to the effectiveness oral health education on oral health
side effects and changes due to gynecologic oncology therapies, data from the OHIP-14
was used. The oncologists at the WCC administered the initial surveys and gave all
participants dental education packet which included, educational material, dental hygiene
tools (extra soft toothbrush, sensitive toothpaste, floss, and PI’s contact information.) The
PI emailed participants four-week post-test survey links via SurveyMonkey to the
provided email. To ensure anonymity of all participants, participants were asked to create
a research ID. No names were included during initial surveys, post-test surveys, and data
analysis.
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Results

Oncologists from the WCC recruited 63 initial participants however, only 36.5%
of participants (N = 23) completed both pre and post-test surveys completely and
correctly. To achieve a confidence level of 95%, margin of error of 5%, and 50%
response distribution, a sample size of 23 (n = 22) is needed. Ages were split into six
different ranges (18-31, 31-40, 41-50, 51-60, 61-70, 71+). Within these age ranges,
30.4% (n = 7) participants were in the 18-50 age range comprising the lowest age group
represented, while 69.6% (n = 16) of participants comprised the 51+ age group,
representing the largest participant population in the study. Education experience showed
(34.8%; n = 8) indicated they had some college experience while 43.5% (n = 10)
indicated they hold a bachelor’s degree are higher. Race/ethnicity showed 65.2% (n = 15)
White or Caucasian, 13.0% (n = 3) African American or Black, 8.7% (n = 2) Hispanic or
Latino, and 8.7% (n = 2) Asian or Pacific Islander. Types of cancer selected were 17.4%
(n = 4) cervical cancer, 56.5% (n = 13) ovarian, fallopian, or peritoneal cancer, 26.1% (n
= 6) uterine cancer, and 4.2% (n = 1) GTD. Cancer treatments included 26.0% (n = 6)
surgery, 13.0% (n = 3) chemotherapy, the majority, 34.8% (n = 8) surgery and
chemotherapy, 13.0% (n = 3) surgery and radiation, 4.3% (n = 1) surgery, chemotherapy,
and radiation, and 8.7% (n = 2) surgery, chemotherapy, and clinical trial. See Table 6 for
full list of participants (N = 23) study demographics.
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Respondents Demographics/ Characteristics
Respondents Characteristics
Age
18-30
41-50
51-60
61-70
71-above

Frequency
1
1
5
5
6
5

Percent (%)
4.3
4.3
21.7
21.7
26.0
21.7

Educational Level
High School
Some College
Associates Degree
Bachelor’s Degree
Post-Graduate

1
8
4
7
3

4.3
34.8
17.4
30.4
13.0

Race
Caucasian or White
African American or Black
Hispanic or Latino
Pacific Islander or Asian
Native Alaskan or Native American
Multiracial or Biracial
A race or ethnicity not listed

16
3
2
2
0
0
0

69.6
13.0
8.7
8.7
0
0
0

Type of Cancer
Cervical
Ovarian, Fallopian, Peritoneal
Vaginal
Vulvar
Uterine
Gestational Trophoblastic Disease

4
12
0
0
6
1

17.4
52.2
0
0
26.1
4.3

Treatment
Surgery
Chemotherapy
Surgery+ Chemotherapy
Surgery+Radiation
Surgery+Chemotherapy+Clinical Trial
Surgery+Chemotherpay+Radiation
Total

6
3
10
3
2
1
23

26.1
13.0
43.5
13.0
8.7
4.3
100
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Statistical Analysis
OHIP-14 scores pre-test scores were used to identify if gynecologic cancer
treatment affected OHRQoL in gynecologic cancer patients during and after treatment.
Pre- and post-test scores were used to analyze if education intervention was successful in
increase OHRQoL of gynecologic cancer patients. Data was also analyzed by OHIP-14
domains, type of treatment, type of cancer, and adverse impact report. A paired t-test was
used to find significance. The null hypothesis there will be no change in OHRQoL after
application of oral health educational.
All participants (N = 23) completed pre-test and post-test surveys. The 14 item
OHIP-14 survey was scored using a five-point Likert-scale where 0 = never, 1 = hardly
ever, 2 = occasionally, 3 = fairly often, 4 = very often. The OHIP-14 scores can range
from 0 to 56 and are calculated by summing the ordinal values for the 14 items. Higher
OHIP-14 scores indicated worse and lower scores indicated better OHRQoL (Slade &
Spencer, 1994). When data was analyzed by all participants (see Table 7). The mean pretest score was 6.7 (SD = 8.4) and a confidence level (95%) of 3.6. The mean post-test
score was 8.8 (SD = 8.4) with a confidence level (95%) of 3.7. A paired t-test was
performed to determine if the education was effective. The mean change in pre-and posttest scores (m = -2.8, SD = 3.8, n = 23) was significantly greater than zero, t (22) = -2.63.
one-tail p < .008, providing evidence that education was effective in producing a change.
A 95% confidence interval (CI) change is ( -3.74, -0.438). A Pearson Correlation was
found to be positively correlated, r (22) =.90, p < .008 indicating a strong correlation
between intervention and a change in OHRQoL.
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Table 7
Pre and Post-Test OHIP-14 Scores
Pre-test
2
8
0
6
10
18
33
5
8
2
4
0
18
21
8
3
0
4
0
0
0
5
0

Post-test
6
12
11
8
15
21
36
6
14
8
3
0
17
15
2
9
0
8
1
0
0
7
4

Difference
-4
-4
-11
-1
-5
-3
-3
-1
-6
-6
1
0
1
6
6
-6
0
-4
-1
0
0
-2
-4

OHIP-14 questions were categorized into seven different dimensions. Functional
limitation, physical pain, psychological discomfort, psychological disability, physical
disability, social handicap, and handicap. The domain scores ranged from 0 to 8. Table 8
shows OHIP-14 pre and post-test scores by domains.
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Table 8
Pre and Post-Test OHIP-14 Scores by Domain for All Participants
Domain
Pre-Test
Mean
Post-Test
Functional Limitation
6
.26
18
Physical Pain
43
1.9
50
Psychological Discomfort
31
1.3
45
Psychological Disability
19
.8
28
Physical Disability
30
1.3
32
Social Handicap
14
.6
12
Handicap
12
.52
16
Total
147
6.4
201

Mean
.8
2.2
2.0
1.2
1.4
.5
.7
8.7

Domain mean pre-test score was 22.1 (SD = 13.0) and the confidence level (95%)
was 12.0. The mean post-test score was 28.7 (SD = 14.6) with a confidence level (95%)
of 13.5. A paired t-test was performed to determine if the education was effective. The
mean change in pre and post-test scores (m = -6.6, SD = 5.7, n = 23) was significantly
greater than zero, t (22) = -3.1. one-tail p < 0.01, providing evidence that education was
effective in producing a change. A 95% confidence interval (CI) change is ( -11.8, -1.4).
A Pearson Correlation was found to be positively correlated, r (22) =. 92, p < 0.01
indicating a strong correlation between intervention and a change in OHRQoL.
Impacts reported “fairly often” or “very often” in pre and post-test. Table 9
demonstrates the prevalence of adverse impacts to QoL pre and post education.
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Table 9
Prevalence of Adverse Impacts on Quality-of-Life Pre and Post-Test
Impact experienced
n
%
n
%
due to problems
reporting
reporting
with teeth, mouth, or
Impact
impact
dentures
pre-test
post-test
Trouble Pronouncing
0
0
0
0
Taste Affected
0
0
0
0
Painful Aching
2
8.7
2
8.7
Uncomfortable to Eat
3
13.0
3
13.0
Been Self Conscious
3
13.0
5
21.7
Felt Tense
1
4.3
2
8.7
Diet Unsatisfactory
1
4.3
0
0
Interrupted Meals
1
4.3
1
4.3
Difficult to Relax
0
0
0
0
Been Embarrassed
4
17.4
3
13.0
Been a Bit Irritable
1
4.3
1
4.3
Difficult Doing Job
0
0
0
0
Life Less Satisfying
1
4.3
1
4.3
Unable to Function
0
0
0
0
Note. Adverse impacts reported when participants answered, “fairly often” and “very
often.”
Pre-test answers showed 13% of respondents answered they found it “uncomfortable to
eat” and had “been self – conscious” while 17.4% participants reported they had “been
embarrassed.” Pre-test responses also showed there was no affect to QoL with trouble
pronouncing, taste affected, difficult to relax, difficult doing job, and unable to function. Posttest showed 13% of respondents reported “uncomfortable to eat” and “been embarrassed,” while
21.7% of respondents reported “been self-conscious.” Post-test respondents felt no difficulty in
their QoL in trouble pronouncing, taste affected, diet unsatisfactory, difficult to relax, difficult
doing job, and unable to function. In the post-test there was a positive change in “been
embarrassed” from 17.4% to 13.0%, this is a change of +4.4%. Data also shows a positive
change in “diet unsatisfactory” from 4.3% to 0%, this is a change of +4.3%. This data shows a
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low percentage of participants felt their OHRQoL had been impacted by gynecologic cancer
treatment. Some areas showed improvement with education packets four weeks after pre-test,
this is a change of +4.4%. Data also shows a positive change in “diet unsatisfactory” from 4.3%
to 0%, this is a change of +4.3%.
Treatment could be categorized into six different categories, surgery,
chemotherapy, surgery + chemotherapy, surgery + radiation, surgery + chemotherapy +
clinical trial, and surgery + chemotherapy + radiation. Table 10 demonstrates pre and
post-test OHIP-14 scores by treatment types.
Table 10
Pre and Post-Test OHIP-14 Scores by Type of Treatment
Type of Treatment

n = # of
Participants
Surgery
6
Chemotherapy
3
Surgery+Chemo
8
Surgery+ Radiation
3
Surg+Chemo+CT
2
Surg+Chemo+Rad
1

OHIP Mean
OHIP
Mean
(pre-test)
(post-test)
40
6.7
54
9
22
7.3
37
12.3
38
4.9
60
7.5
54
18
51
17
0
0
1
.5
0
0
0
0

Diff.
-14
-15
-21
3
-1
0

The mean pre-test score was 25.8 (SD = 22.4) and a confidence level (95%) of
23.5. The mean post-test score was 33.8 (SD = 26.9) with a confidence level (95%) of
28.2. A t-test was performed to determine if education was effective. The mean change
in pre and post-test scores (m = -8.0, SD = 9.9, n = 23) was significantly greater than
zero, t (22) = -2.0. one-tail p = 0.05, providing evidence that education was effective in
producing a change. A 95% confidence interval (CI) change is ( -18.4, 2.4). A Pearson
Correlation was found to be positively correlated, r (22) =.94, p = 0.05 indicating a strong
correlation and significance.
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When examining individual treatment types, surgery + radiation pre-test results
showed a total score of 54 mean of 18 and post-test total score was 51 with a mean of 17.
This reveals a difference of one, revealing that OHRQoL in the surgery + radiation group
improved with education. Data also showed participants who were treated with surgery +
chemotherapy + radiation had a score of zero, revealing that their teeth, mouth, or
dentures had not been affect from treatment nor influenced by educational intervention.
Table 11 demonstrates how participants could be categorized into four types of
gynecologic cancers. Cervical, ovarian, fallopian, peritoneal, uterine, and GTD. Table 11
shows the difference in pre and post-test OHIP-14 scores by type of gynecologic cancer.
Table 11
Pre and Post-Test OHIP-14 Scores by Type of Cancer
Type of cancer
Cervical
O, F, P
Uterine
GTD

n = # of
Participants
4
12
6
1

OHIP
(pre-test)
26
89
38
2

Mean
6.4
7.34
6.3
2

OHIP
Mean
(post-test)
40
10
123
10.25
34
5.7
6
6

Diff.
-14
-34
4
-4

When data was analyzed by type of cancer the mean pre-test score was 38.8 (SD =
36.7) with a confidence level (95%) of 58.4. The mean post-test score was 50.8 (SD =
50.4) with a confidence level (95%) of 80.2. A paired t-test was performed to determine
if the education was effective. The mean change in pre and post-test scores (m = -12.0,
SD = 16.4, n = 23) was significantly greater than zero, t (22) = -1.5. one-tail p < 0.12,
providing evidence that education was not effective in producing a change. A 95%
confidence interval (CI) change is (-38.1, 14.1). A Pearson Correlation was found to be

PILOT STUDY of OHRQoL DURING GYN CANCER TREATMENT
positively correlated, r (22) =.98, p < 0.12 indicating a strong correlation but no
significance.
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Discussion
Summary of Major Findings
Upon statistical analysis participants (N = 23) a mean score of 6.7 in pre-test to a mean of
8.8 in the post-test. Pearson Correlation was .90 showing a strong correlation and a P (T
< +t) one-tail of 0.008. p was set to (p < 0.05), this shows a significance when total
sample was analyzed. Significance was found in data when participants were grouped by
domains (p < .001). No significance was found when participants were grouped by
treatment type (p = 0.05) and cancer type (p < 0.12). Therefore, the evidence in this study
suggests the educational intervention did influence participants post-test OHIP-14 scores,
thus decreasing OHRQoL in gynecologic cancer patients. Severity scores were calculated
by summing responses and higher scores were indicative of poorer OHRQoL (Mata et al.,
2015). This chapter discusses the use of the OHIP-14 survey to measure OHRQoL in
gynecologic cancer patients pre and post dental education to answer the following
research questions.
Discussion
Impact of gynecologic cancer treatments on OHRQoL
Results show that prior to education being implemented, gynecologic cancer
patients had low OHIP-14 scores. When data was analyzed by all participants (see Table
8) the mean pre-test score was 6.7 (SD = 8.4). Pre-test scores revealed that gynecologic
cancer treatment had a slight impact on OHRQoL. These pre-test results indicated most
participants (see Table 8) did not have adverse effects that are usually seen in other types
of cancers. The PI hypothesized that no matter what type of cancer a patient is being
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treated for radiation, chemotherapy, and CT would affect the mouth thus affecting
OHRQoL. These results indicated gynecologic cancer patients’ mouths are not affected in
the same way as head and neck cancer. This study’s impact report post-test results
concluded that 13% of respondents reported “uncomfortable to eat” and “been
embarrassed” while 21.7% of respondents reported “been self-conscious.” Zero
respondents reported trouble pronouncing, taste affected, diet unsatisfactory, difficult to
relax, difficult doing job, and unable to function. In the post-test there was a positive
change in “been embarrassed” and “diet unsatisfactory.” This study’s result is
inconsistent with results from other studies. Research by Bhallal et al. (2015)
demonstrated patients with head and neck cancer about 53.16 % reported they were
totally unable to function because of problems with their teeth, mouth, or dentures. About
45.57% felt that life in general was less satisfying because of problems with teeth, mouth,
or dentures. The findings of this study were also inconsistent with the study by
Lawerence et al. (2008) where 40.51% felt uncomfortable to eat, whereas 37.97% said
they had unsatisfactory diet that interrupted meals. Similarly, 40.51% reported they felt
self-conscious or tense about their teeth which could be the psychological effect of their
oral taste. Research by Tesic et al. 2020 found lower OHIP-14 scores (i.e., lower impacts
on oral health) for patients with head and neck cancer and most frequently present among
patients who had only surgery as a therapeutic procedure compared to those who had
surgery accompanied with radiation and chemotherapy (p < 0.01). This is consistent with
findings from this study in that participants who only had surgery had lower pre-test and
post-test OHIP-14 scores compared to those participants who had radiation and
chemotherapy. The results from this study showed gynecologic cancer patients are less
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likely to experience oral compromise of daily living during treatment, as a result lower
OHIP-14 scores meaning healthier OHRQoL.
Since this type of research has not been studied on this type of population
relatability is unavailable. What is apparent from these results is that this populations’
oral health is not affected by cancer treatment, which is not what the PI anticipated.
Research by Marquez-Arrico et al. (2019) found an association Chi2: p = 0.000 between
educational level and oral health knowledge. It was observed that as subject’s educational
level increased, so did their level of oral health knowledge, with a linear tendency among
the categories. This data can be related to this study because this population had higher
education levels with (n = 14) 60.8% of participants having an associate degree or higher.
Because these participants had higher educational experience, they may have known to
seek dental care prior to starting treatment. This phenomenon could explain why this
population had lower pre-test OHIP-14 scores. Research from Zandbergen et al. (2019)
found that among endometrial and ovarian cancer patients, HRQoL improved within 6
months after initial treatment. This can be related to this study as the PI is unaware if
participants were receiving treatment or had concluded treatment, however if most
participants had finished treatment, then results would seem sensible as to why OHIP-14
scores were low prior to education intervention being implemented.
Is there an improvement in OHRQoL secondary to oral hygiene education
After education was implemented and data was analyzed (see Table 7), post-test
mean score was 8.8, p < .008, showing significance and an increase in OHIP-14 scores
(higher impacts on oral health). The PI hypothesized OHIP-14 scores to decrease over
four weeks, however, results showed mean test results increased by -2.1, which is a very
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slight change. However, this is a negative change in OHRQoL. These results were
unanticipated. The PI predicted that OHIP-14 scores would decrease with the
implementation of education material and oral hygiene care tools. These results are
consistent with other studies with an increase in OHIP-14 scores during cancer treatment.
When data was analyzed individually, (n = 4) 17.4% of participants’ (see Table 7) OHIP14 scores did decrease demonstrating an increase in their OHRQoL after education was
implemented. This suggests education can improve OHRQoL in some individuals.
However, (n = 15) 65.2% of participants had higher OHIP-14 scores and a decrease in
OHRQoL after education was implemented. This increase in OHIP-14 scores was seen in
research by Mata et al. (2015) who reported that where there is a wide range of responses,
individual issues are usually camouflaged by reporting group mean scores.
Post-test results for type of treatment concluded that a p = 0.05 was shown, giving
no significance. However, surgery + radiation (n = 3) pre-test results showed a mean of
18 and post-test mean of 17. This shows a difference of one, revealing the education
intervention improved OHRQoL within this group, but no significance was found.
Post-test results for type of cancer, concluded p < 0.12 was shown, giving no
significance. However, uterine cancer (n = 6) pre-test mean was 6.3 and post-test mean
was 5.6 revealing a difference of 0.7 with no significance. This suggests an education
intervention improved OHRQoL within this group. One may infer that in this pilot study,
patients with uterine cancer either had less deleterious effects from treatment and or used
the education materials.

PILOT STUDY of OHRQoL DURING GYN CANCER TREATMENT

60

Multi-disciplinary team approach
Results from this study indicate after implementation of education, OHIP-14
scores increased, signifying lower QoL over the four-week study. This demonstrates this
population is still vulnerable to oral implications due to treatment even after education is
implemented. Research from Zandbergen et al. (2019) shows that HRQoL changes over
time. Similarly, OHRQoL has the ability to change over time based upon factors causing
negative oral changes affecting OHRQoL prior, during, and after treatment concludes.
For this reason, approaching oral health of gynecological cancer patients by a team
approach (see Figure 3) may be beneficial to determine individual oral health needs and
tailor oral health care tools and education to the individual. Research by Elad et al. (2015)
emphasized the importance of advocating improved oral care of patients undergoing
chemotherapy/hematopoietic stem cell transplantation by developing an integrated
treatment team including medical, dental, nursing, nutrition, physical therapy, and
counseling providers. Training and continuing education programs would ensure
knowledge diffusion to an extensive community of health care providers, which in turn
could make a positive impact on patients’ health care. Figure 3 illustrates a flow chart on
how this type of team-based collaboration can work together to improve OHRQoL in
gynecologic cancer patients.
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Figure 3
Suggested Collaboration of Hematology/Oncology and Oral Medicine/Dental Teams as
Part of Basic Oral Care for Oncologic Patients

Note. From “Basic oral care for hematology-oncology patients and hematopoietic stem
cell transplantation recipients: a position paper from the joint task force of the
Multinational Association of Supportive Care in Cancer/International Society of Oral
Transplantation (EBMT),” by Elad et al., 2015, Support Care Cancer, 2(1), 223-236.
Copyright 2015 by Creative Commons.
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Research by Velji et al. (2006) employed an individualized education program
symptoms management for distressed women receiving radiation therapy for gynecologic
cancers to improve their QoL. Their results showed women who utilized the
individualized education program intervention showed a significant decrease in symptom
distress and showed fewer worsening symptoms of distress pain, fatigue, and nausea at
the end of the radiation treatment than those who received usual care. This research
supports the creation of individual oral health programs being implemented into
gynecologic cancer offices to decrease oral health symptoms during cancer treatment.
This program has the potential to effectively manage patients undergoing treatment thus
positively impacting their QoL. The results of the study indicated that implementing oral
health education did show positive results in some individuals however results were not
significant.
Limitations
Data was collected from a small sample size of participants (N = 23). The PI was
unaware of participants’ prior dental health, history, education as well as if gynecologic
treatment was on-going or had concluded. Participants were only recruited based-on their
diagnosis of a gynecologic cancer; dental health, history, and education was unknown at
the start of the study. Time was also a factor in the study. The PI was under a time
constraint from what was originally planned. Because of COVID-19 and working with a
vulnerable population, the PI was unable to implement face-to-face oral health
educational presentation to all participants and provide one-on-one individualized oral
health education and instruction to participants. Participants were not monitored during
the four-weeks between pre- and post-test surveys and may have not read the dental
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health education material nor used dental hygiene tools they were provided. As stated
above, reading material may have been overwhelming for participants or written at a
level that was not appropriate for this population. The PI also did not have participants
fill out global transition questions after their post-test survey. These qualitative questions
refer to participants’ self-reporting oral health after the four weeks and if the educational
material and dental hygiene tools made an impact in their QoL. The Hawthorne affect
could have occurred because participants were given new knowledge and felt their scores
were being observed, thus affecting OHIP-14 post-test scores.
Recommendations/Suggestions for Future Research
This pilot study proved the feasibility of such a study. Recommendations for
study replication include use of a control group, recruiting newly diagnosed gynecologic
cancer patients, and recording oral health before, during, and after gynecologic cancer
treatment(s). Providing oral health education prior to the patient starting or receiving any
type of treatment would provide a baseline on how oral health education plays a part in
improving OHRQoL during and after gynecologic treatment. Future research should also
include documenting if gynecologic cancer patients suffer from oral changes that are seen
in other types of cancer treatment. These include hypersalivation, loss of sensory
function, limited opening, infection, mucosal changes, caries, periodontal disease
progression, risk of mucosal injury, osteoradionecrosis, poor esthetics, trouble speaking,
eating, and swallowing. Finally, further investigation should evaluate the correlation
between age, education level, income, and livelihood.
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Conclusion
Although the results showed an increase in OHIP-14 scores thus decreasing
OHRQoL, when data was analyzed individually some participants OHRQoL improved
after implementation of education. This pilot study is the first of its kind to investigate if
gynecologic cancer patients’ OHRQoL is affected during cancer treatment and if so if
education may help decrease negative changes and increase OHRQoL during and after
treatment. Although the hypothesis that education would improve the OHQoL the study
limitations and variables prevented meeting significance in data analysis. This pilot study
proved the feasibility of such a study. Literature and this study support the need for
advocating and implementing individualized oral health education and oral hygiene
demonstration prior to beginning gynecologic cancer treatment. Additionally, data
suggests a need for collaboration between dentistry and medicine in treating women with
gynecological cancer.
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Appendix A
OHIP-14 Survey
Distribution of OHIP-14 items, ranging from 0 (Never), 1 (Hardly ever), 2
(Occasionally), 3 (Fairly often), to 4 (Very often)
Question Description of item
#
0
1 2 3
I
Have you had trouble pronouncing any
words because of problems with your teeth,
mouth, or dentures?
2

Have you felt that your sense of taste has
worsened because of problems with your
teeth, mouth, or dentures?

3
4

Have you had painful aching in your mouth?
Have you found it uncomfortable to eat any
foods because of problems with your teeth,
mouth, or dentures?

5

Have you felt self-conscious because of
problems with your teeth, mouth, or
dentures?
Have you felt tense because of problems
with your teeth, mouth, or dentures?
Has your diet been unsatisfactory because of
problems with your teeth, mouth, or
dentures?
Have you had to interrupt meals because of
problems with your teeth, mouth, or
dentures?
Have you found it difficult to relax because
of problems with your teeth, mouth, or
dentures?
Have you been a bit embarrassed because of
problems with your teeth, mouth, or
dentures?
Have you been a bit irritable with other
people because of problems with your teeth,
mouth, or dentures?

6
7
8
9
10
11

4
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12

Have you had difficulty doing your usual
jobs because of problems with your teeth,
mouth, or dentures?
13
Have you felt that life in general was less
satisfying because of problems with your
teeth, mouth, or dentures?
14
Have you been totally unable to
function because of problems with your
teeth, mouth, or dentures?
Note. From “Derivation and validation of a short-form oral health impact profile,” by Slade.,
1997, Community Dentistry and Oral Epidemiology. Copyright 1997 by John Wiley & Sons,
Inc.
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Appendix B
Demographic Survey
Age
a) 18-30
b) 31-40
c) 41-50
d) 51- 60
e) 61-70
e) 61-70
f) 71- above
Education Experience
a) High School
b) Some College
c) Associates degree
d) Bachelor’s degree
e) Post- Graduate
f) Other
Race
a) Caucasian or White
b) African American or Black
c) Hispanic or Latino
d) Pacific Islander or Asian
e) Native Alaskan or Native American
f) Multiracial or Biracial
g) A race or ethnicity not listed here

Type of Cancer
a) Cervical
b) Ovarian, Fallopian, Peritoneal
c) Vaginal
d) Vulvar
e) Uterine
f) Gestational Trophoblastic Disease
Treatment (select all that apply)
a) Surgery
b) Chemotherapy
c) Radiation
e) Clinical Trial
f) None
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Informed Consent Form
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Appendix D
Educational Script for Oncologists and Medical Assistants (Ma’s) at the WCC
Hello, and thank you for allowing me to conduct my thesis study at the WCC. My thesis topic
is oral health related quality of life (OHRQoL) during gynecologic cancer treatment. My study will be
looking at how gynecologic cancer treatments affect OHRQoL and if supplying participants with
dental hygiene tools and education will this improve OHRQoL using a four- week post survey. The
survey that I will be using is the OHIP-14 by Slade. The Oral Health Impact Profile (OHIP) is the
most widely used QoL survey that evaluates the influence of oral diseases on individuals. The short
form OHIP-14 by Slade, contains 14 items grouped into seven dimensions of impact: functional
limitation, physical pain, psychological discomfort, physical disability, psychological disability, social
disability, and handicap. OHRQoL survey has a broader appreciation of the impact of oral health. It
should provide the basis for any oral health program development. Oral health care providers are
urged to integrate the OHRQoL concept into their daily practice to improve the outcome of their
services.
I am asking you to recruit all gynecologic cancer patients at the Women’s Cancer Center, who
fit the study’s inclusion criteria, which includes any patient who has been diagnosed with a
gynecologic cancer and is 18 years and older that can give their own consent and does not need an
advocate. All participants will be asked to participate in a pre-test survey and a four- week post- test
survey that will be emailed to them four weeks after initial surveys are completed. Participants will fill
out consent forms, pre-test surveys (demographic survey and OHIP-14), and will be given a dental
care package which includes at home instructions, extra soft toothbrush, fluoride toothpaste, floss, and
dental education brochures that included; National Institute of Health (NIH) Oncology Team Oral
Complications of Cancer Treatment: What the Oncology Team Can Do, NIH Chemotherapy and Your
Mouth, NIH Three Good Reasons to See a Dentist Before Cancer Treatment, and NIH Oncology
Pocket Guide to Oral Health: Prevention and management of oral complications Head and Neck
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Radiation Therapy, Chemotherapy, and Hematopoietic Stem Cell Transplantation.
All Participants will complete consent forms, surveys, and place all documents in the included
self -sealing envelope and seal it. Envelopes will be collected by oncologist or MA and will be placed
into a locked drawer at the WCC until I can pick them up. Participants will be contacted four weeks
after initial surveys by the email they provided with a SurveyMonkey link to the four-week post- test
survey.
Please know that your own participation and your patients’ participation are NOT required and
you and your patients can opted out of the study at any time.
Thank you again for allowing me to conduct my study at your office and with your patients.
Oral health is such a passion of mine and I look forward to working with all of you. Does anyone have
any questions?

If you have questions in the future, please do not hesitate to call or email.
Kushnir384@gmail.com
skushnir@eagles.ewu.edu
(619)240-4249
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